Once-weekly Isoniazid and Rifapentine for 12 Weeks for the Treatment of Latent Tuberculosis Infection: Clinical Utility and Cost-Effectiveness
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.